Literature DB >> 14679676

[Adverse cardiovascular and central neurologic reactions to sympathomimetics used as nasal decongestants: results of the French National Pharmacovigilance Survey].

Pascale Olivier1, Aurelie Dugué, Jean-Louis Montastruc.   

Abstract

Remedies for coughs and colds often contain both an indirect sympathomimetic agent plus another drug (anti-inflammatory, analgesic or antibiotic, etc.). In France, oral sympathomimetics are available over the counter, and preparations for topical use (nasal sprays or drops) require a medical prescription. Using the French Pharmacovigilance database, we performed a retrospective study to identify cardiovascular and neurological adverse drug reactions (ADRs) associated with the use of nasal decongestants containing a sympathomimetic agent. Of a total of 165 ADRs. 15 were strokes or cerebral haemorrhages. We also found the following: 67 cases of arterial hypertension, 33 of convulsions, 28 of headaches and 24 of vasomotor symptoms involving the extremities. In most of these cases, misuse or a predisposing factor was found (such as a history of arterial hypertension or headache, the combination of two decongestants, long-term use, etc.). The incidence of cardiovascular or neurological ADRs with cold remedies seems 'very rare' but some of these reactions, mainly stroke, are 'serious'. However, there is no available clinical evidence showing the benefit of such agents after repeated use over several days. Since most of the nasal decongestants are freely available without prescription, drug information is needed to advise prescribers and also patients about risk of 'serious' ADRs with these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14679676     DOI: 10.2515/therapie:2003055

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  2 in total

1.  Decongestant use and the risk of myocardial infarction and stroke: a case-crossover study.

Authors:  Lamiae Grimaldi-Bensouda; Bernard Begaud; Jacques Benichou; Clementine Nordon; Olivia Dialla; Nicolas Morisot; Yann Hamon; Yves Cottin; Elie Serrano; Lucien Abenhaim; Emmanuel Touzé
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 2.  In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine.

Authors:  Antonio Munafò; Stefano Frara; Andrea Giustina; Renato Bernardini; Norberto Perico; Rosaria Di Mauro; Monica Cortinovis; Chiara Burgaletto; Giuseppina Cantarella; Giuseppe Remuzzi
Journal:  Rev Endocr Metab Disord       Date:  2021-05-04       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.